3 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMORecruiting
Primary objective:to investigate and compare the effect of EUS-GE and SGJ on patients* short- and long-term ability to eat* (time to oral intake, and reinterventions for persistent or recurrent symptoms of GOO within 6 months of follow-up,…
Approved WMOPending
To investigate the reliability and feasibility of PK-guided prophylactic dosing of factor concentrates in hemophilia A and B patients (predictive performance).